Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.

MLA

Chen, Yi-Bin, et al. “Vedolizumab for the Prevention of Intestinal Acute GVHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized Phase 3 Trial.” Nature Medicine, vol. 30, no. 8, Aug. 2024, pp. 2277–87. EBSCOhost, https://doi.org/10.1038/s41591-024-03016-4.

APA

Chen, Y.-B., Mohty, M., Zeiser, R., Teshima, T., Jamy, O., Maertens, J., Purtill, D., Chen, J., Cao, H., Rossiter, G., Jansson, J., & Fløisand, Y. (2024). Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nature Medicine, 30(8), 2277–2287. https://doi.org/10.1038/s41591-024-03016-4

Chicago

Chen, Yi-Bin, Mohamad Mohty, Robert Zeiser, Takanori Teshima, Omer Jamy, Johan Maertens, Duncan Purtill, et al. 2024. “Vedolizumab for the Prevention of Intestinal Acute GVHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized Phase 3 Trial.” Nature Medicine 30 (8): 2277–87. doi:10.1038/s41591-024-03016-4.